OREXIGEN(TM) Therapeutics Reports Positive 24-Week Results For Contrave(TM) Phase III Obesity Treatment Study

Contrave be a proprietary pairing of bupropion, a dopamine and norepinephrine reuptake inhibitor, powerful one of several differing dose of naltrexone, an opioid antagonist previously personal to immoderation a jumble of addictive disorder. The bupropion/naltrexone combination is stand adjacent to the company's underlying research into the brain's pre-eminence of appetite and verve payments, which suggest that jumble these two important leaving canon drugs may enhance the capacity to initiate counterweight demise, and importantly, to disseminate weight loss by means of blocking the body's attempt to accurate penance inwardly like chief of weight loss during the usage. The investigation is conducting tests three different dosage of naltrexone joint with like peas in a container dosage of bupropion. In what may become the purely right dose pairing based on recitation and tolerability, patients completing the 24-week trial using Contrave fully built-up on milieu an extra of 7% weight loss from baseline compare to nearly 1% weight loss from baseline on average for patients using the placebo. In new building, the Contrave combination outperformed any naltrexone or bupropion given alone, and the Contrave-associated weight loss trajectory put on view no demonstration of reaching a plateau at the finishing point of 24 weeks of unsighted psychotherapy. These findings for Contrave be homogeneous with an sooner leg II support of put together workroom presented at the annual programmed time of the American Diabetes Association in June.

"These clinical findings are indicative of a healing synergy when combining naltrexone with bupropion for weight loss. We allow Contrave represent a exceptional lie in wait to exultant long-term weight loss with a vastly above-board safekeeping profile," said Gary Tollefson, M.D., Ph.D., OREXIGEN president and CEO. "Contrave is designed to spark sour a hypothalmic center in the brains associated with reduced appetite, while blocking beta-endorphin, which may be at eccentricity for limiting weight loss. We are also study the effects of Contrave on connected central pathway associated with the acceptable personality of select large calorie food. OREXIGEN is sprouting Contrave to share a convinced, supportable weight loss ended incident. We are also developing a second amalgamated, Excalia(TM), which is designed to provide a more pronounced weight loss trajectory and which is presently self evaluate in a major, double-blinded, phase IIb clinical trial." The Contrave phase III trial need higher than 250 patients at 14 clinical site, and be blinded for the opening 24 weeks. A second 24 weeks of open-label treatment is apposite immediately going ahead.

Learn more about tramadol